US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

• DOI: 10.1001/jamaneurol.2021.3126
• Publication Date: 2021-09-13T15:00:42Z
• Authors: Vincent Planche; Nicolas Villain
• Keywords: Clinical Trials as Topic; [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology; Amyloid beta-Peptides; United States Food and Drug Administration; Antibodies, Monoclonal, Humanized; United States; 03 medical and health sciences; 0302 clinical medicine; Alzheimer Disease; Humans; Drug Approval; Biomarkers

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2023 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal